While $MACK is mentioned in forvorable light in the below article I copied for $CPRX, I am not thinking of buying $MACK at this time. While the chart looks great, they no longer have a significant drug in the pipeline as they sold off Onyvide to Ipsen and are back to having two candidates in Phase II trials and one candidate beginning Phase I testing.

https://www.americanconsumernews.net/scripts/...px?Zacks=1